(P \.001). Of note, patients with Medicaid remained significantly more likely to present at a late stage (P \ .001) compared with patients in all insurance status categories when only white patients were considered (Table I) .
These findings suggest that insurance type alone, specifically Medicaid, may be involved in the disparities of melanoma stage at diagnosis. Potential explanations for this are decreased utilization of cancer screening in Medicaid subscribers and provider discrimination based on insurance status. Prior research has shown that Medicaid patients face lower acceptance rates for dermatology appointments (32% acceptance for those with Medicaid, 85% for those with Medicare, and 87% for those with private insurance) and longer wait times (50 days average for those with Medicaid and 37 days average for those with Medicare and private insurance), 3 possibly contributing to poorer outcomes.
A limitation of our study is that the data do not incorporate changes in insurance status before or after the time of diagnosis, given that length of time enrolled in Medicaid has been shown to be a significant variable affecting melanoma stage at diagnosis. 4 Patients with cancer who are on Medicaid have been shown to have comparatively later-stage diagnoses, 5 but few studies have considered patients with melanoma specifically. This study provides evidence that insurance type alone is associated with stage at melanoma diagnosis. Given that a larger proportion of patients from minority populations have Medicaid, 2 it is likely that insurance status is contributing to the current racial disparities in melanoma outcomes. In light of the frequently debated and shifting configuration of health insurance in this country, it is important that providers 
Effects of curettage after shave biopsy of unexpected melanoma: A retrospective review
To the Editor: Curettage, sometimes combined with electrodessication, has been well-documented in treating nonmelanoma skin cancers (NMSCs).
1
Probable NMSCs may be curetted immediately after shave biopsy, lowering health care costs, increasing access for patients, and reducing delays in care. 2, 3 However, providers may be cautious to curette potential NMSCs without histopathologic diagnoses, for fear of curetting unexpected melanomas. In our institution, most lesions clinically suggestive of NMSC of the trunk and extremeties are subjected to shave biopsy and then immediately curetted (with or without electrodessication), with additional treatments based on histopathology. 4 The curetted tissue is not routinely sent for histopathologic diagnosis. Here, we report 8 cases of curettage after shave biopsy of unexpected melanomas.
Since 2012, the Mayo Clinic Arizona Department of Dermatology has recorded biopsy and treatment methods on pathology requisitions. After institutional review board approval, the Mayo Clinic Arizona CoPath database was queried for unexpected melanomas that were curetted only or curetted with electrodessication after biopsy from December 2012 to August 2017. A total of 7764 lesions were subjected to shave biopsy and immediately curetted (with or without electrodessication) in 5431 patient encounters. Eight (0.10%) curetted lesions were unexpectedly found to be melanoma on the basis of histopathology (Fig 1 and Table I ). At the time of biopsy, all the lesions were clinically suggestive of basal cell carcinoma.
On pathologic review, 6 lesions were found to be superficial spreading melanoma, one lesion was primary dermal spitzoid or metastatic melanoma, and 1 lesion was melanoma in situ. Excluding the melanoma in situ, the mean (SD) depth was 0.94 (0.62) mm, with a mean (SD) 5.57 (7.23) mitoses/ mm 2 . Deep margins were focally positive in 2 biopsy specimens, and broadly positive in 4 biopsy specimens. All biopsy specimens had peripheral margin involvement.
All patients were informed of partially transected melanoma on their biopsy specimen and counseled regarding sentinel lymph node evaluation. All lesions were re-excised, and 2 patients elected to undergo sentinel lymph node biopsy. Among those treated with wide local excision, residual disease was found in 4 patients, with invasive involvement in 1 patient (1.58 mm). Final margins and sentinel lymph nodes were negative in all patients. One patient died of unrelated causes 6 months after the initial biopsy. The remaining 7 patients have continued follow-up, for a mean (SD) of 23 (14) months without recurrent disease.
If NMSCs are immediately curetted after shave biopsy, melanomas masquerading as NMSCs may be curetted as well. In our study, 8 of 7764 curetted lesions were later unexpectedly found to be melanomas by pathologic examination. Transection of melanoma has not been shown to affect outcomes or survival 5 ; thus, additional curettage after initial biopsy may likewise have little effect. Our results suggest low risk (0.1%) of curettage of unexpected melanoma after treatment of presumptive NMSCs. A total of 7 cases of curettage of unexpected melanoma were followed for a mean of 23 months, and resulted in no immediate harmful sequelae such as spreading of the tumor, requiring unusual surgical management, or early recurrence. Further follow-up and larger patient studies are required to determine long-term adverse outcomes.
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